Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx label changes affect OTC use?

This article was originally published in The Tan Sheet

Executive Summary

FDA's proposal to update the format of the pregnancy and lactation sections of drug labeling may encourage women to use "safe and effective products," including Rx drugs that "they might otherwise avoid" because of safety concerns, the agency says. The rule published in the May 29 Federal Register would require labels to include "up-to-date information on the risks and benefits of prescription drugs" on pregnant women, their fetuses and lactation. FDA cites studies that found pregnant women often take OTC drugs and dietary supplements instead of prescription products because they perceive those products are safer, even though safety information on OTC products and supplements "is as limited, if available at all, as that for prescription drugs"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel